**Supplementary file 1**

**Additional demographics of randomized participants included in untreated and 48 week short-course ART analyses**

|  |  |  |
| --- | --- | --- |
|  | **Randomised to no therapy (SOC) at PHI, and sampled at week 0**  **N = 51** | **Randomised to 48 weeks of ART (ART-48) from PHI and sampled at week 48**  **N=47** |
| **Patients with a Total HIV-1 DNA measurement** | 51 (100%)† | 47 (100%)\* |
| **Patients with an Integrated HIV-1 DNA measurement** | 38 (74%)† | 47 (100%)\* |
| **Total HIV-1 DNA**  **(log10 copies/million CD4 cells)+** | 4.01 (3.49-4.29) † | 3.25 (2.90-3.44)\* |
| **Integrated HIV-1 DNA**  **(log10 copies/million CD4 cells) +** | 3.6 (3.3-3.8) † | 3.0 (2.7-3.2)\* |
| **Time since seroconversion at enrolment (days) +** | 73 (49-93) | 76.5 (52.0-96.9) |
| **ART Duration (weeks)+** | 0 | 48 (47.7 – 48.7) |
| **Baseline CD4 cell count**  **(cells/µl) +** | 550 (400 – 691) | 565 (439-732) |
| **Log10 RNA copies/ml+** | 4.73 (4.14 – 5.26) | All <50 |
| **Country of recruitment** | Australia 8 (15.6%)  Italy 7 (13.7%)  Brazil 5 (9.8%)  UK 31 (60.8%) | Australia 5 (10.6%)  Italy 5 (10.6%)  Brazil 3 (6.4%)  UK 34 (72.3%) |
| **Sex** | Female 2 (4.0%)  Male 49 (96%) | Female 1 (1.9%)  Male 51 (98%) |

† determined at pre-therapy baseline (trial week 0). \* determined at week 48, prior to TI. **+**median (interquartile range). SOC: Standard of Care trial arm.